Experimental Hematology and Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Mutational signatures of synchronous and metachronous brain metastases from lung adenocarcinoma
In conclusion, CSF liquid biopsies have a priority in detecting gene alteration. A comprehensive comparison of molecular profiling between SBM and MBM revealed the most frequently altered genes in both groups wereEGFR andTP53, but with different exon point mutations. RTK-RAS and TP53 pathways were the most affected pathways. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - June 13, 2023 Category: Cancer & Oncology Source Type: research

Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials
ConclusionPatients withTP53 wild type, ctDNA nonshedding, or clearance showed superior efficacy of pyrotinib in  patients withHER2-mutated advanced NSCLC, which might be helpful to guide the utility of pyrotinib in clinical setting.Trial registration: The patients were from two registered clinical trials (ClinicalTrials.gov: NCT02535507, NCT02834936). (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - June 9, 2023 Category: Cancer & Oncology Source Type: research

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
AbstractHepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste homolog 2 (EZH2, a histone methyltransferase) is suggested to be one of the principal factors that mediates oncogenesis by acting as a driver of epigenetic alternation. Recent studies show that EZH2 is widely involved in proliferation and metastasis of HCC cells. In this review, the functions of EZH2 in HCC progression, the role of EZH2 in tumor immunity and the application of EZH2-related inhibitors in HCC ther...
Source: Experimental Hematology and Oncology - June 2, 2023 Category: Cancer & Oncology Source Type: research

Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications
AbstractSoft-tissue sarcoma (STS) are a heterogeneous group of rare tumors with different biological behavior that are fatal in more than 40% of cases, due to their metastatic evolution and inadequate treatment options. ATR inhibition already showed an activity, even if modest, in broad pre-clinical models of STS. By using genome-wide CRISPR/Cas9 library screening, we identified ATM signaling network genes as critical drivers for resistance to the specific ATR inhibitor AZD6738. The role of such genes in resistance to AZD6738 was confirmed by using CRISPR/Cas9 knockout models. More strikingly, the ATM inhibitor AZD0156 wor...
Source: Experimental Hematology and Oncology - May 31, 2023 Category: Cancer & Oncology Source Type: research

Utility of indium-111 platelet scintigraphy for understanding the mechanism of thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
ConclusionWe show that IPS can be a useful tool to identify the mechanism and guide treatment of a chronic thrombocytopenia increasing the bleeding risk in patients with MDS. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - May 30, 2023 Category: Cancer & Oncology Source Type: research

ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer
ConclusionsThe significant heterogeneity of luminal, immune, and interstitial cells in PCa LNM may not only directly contribute to tumor progression, but also indirectly result  in TME immunosuppression, which may be the cause of metastasis in PCa and in which MYC played an role. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - May 23, 2023 Category: Cancer & Oncology Source Type: research

The gut microbiota as a booster for radiotherapy: novel insights into radio-protection and radiation injury
AbstractApproximately 60 –80% of cancer patients treated with abdominopelvic radiotherapy suffer post-radiotherapy toxicities including radiation enteropathy and myelosuppression. Effective preventive and therapeutic strategies are lacking for such radiation injury. The gut microbiota holds high investigational value for deepening our understanding of the pathogenesis of radiation injury, especially radiation enteropathy which resembles inflammatory bowel disease pathophysiology and for facilitating personalized medicine by providing safer therapies tailored for cancer patients. Preclinical and clinical data consist entl...
Source: Experimental Hematology and Oncology - May 22, 2023 Category: Cancer & Oncology Source Type: research

Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis
In this study, we identify a core set of direct NRF2 targets that are involved in ferroptosis, a novel form of cell death. Of particular interest, we find that glutathione peroxidase 4 (GPX4) is a key ferroptosis gene that is consistently upregulated in AML, and high expression of GPX4 is associated with poor prognosis for AML patients. Importantly, simultaneous inhibition of NRF2 with ML385 and GPX4 with FIN56 or RSL3 synergistically targets AML cells, triggering ferroptosis. Treatment with ML385  + FIN56/RSL3 resulted in a marked reduction in NRF2 and GPX4 expression. Furthermore, NRF2 knockdown enhanced the sensitiv...
Source: Experimental Hematology and Oncology - May 17, 2023 Category: Cancer & Oncology Source Type: research